Well I just reread it and for your reading pleasure I offer the text again here. There is no discussion of dispensing machines. There is no mention of FDA approval. There is only vague reference to appropriate regulatory agency's. I really don't care what the Counsel said to you on the phone. In fact this was exactly why I don't call the company as you have suggested. It is exactly these kinds of misunderstandings. The only authority that can be relied on as far as the company statements are concerned are the statements in the Press Releases and financial filings. If they are in error, then they should be corrected.
(BSNS WIRE) National Boston Medical Inc. Today Announces Product Approval, Launches
Business Editors/Health & Medical Writers
POMPANO BEACH, Fla.--(BW HealthWire)--Nov. 3, 1998--National Boston Medical (OTC BB:NBMXD) is pleased to announce it has completed development of its new series of VERTA infection control product for use in dental offices. The company has now received approval from the appropriate regulatory agency's of the following products for sale in the US and Canada. The launch of the VERTA series concludes many months of research and development to develop and acquire products, which will position NBM as the leader in the fight against cross contamination.
Today's product launch includes the VERTA LINE, VERTA VAC, and VERTA SON. VERTA LINE protects patients from cross contamination and Bacterial Aerosols, and eliminates Pseudomontis and Psudoaerugenosa from self-contained dental water devices. VERTA VAC is a uniquely newly developed Bio-Formulation consisting of a synergistic blend of selected activity resulting in a breakdown of tissues, oil, blood, and organic matter in dental evacuation systems. The third product, VERTA SON, was developed for pre-soaking dental instruments to remove blood, and organic matters minimizing the need to hand clean instruments.
These products expand on or replace technology presently in use in dental practice today. Dental practices today are becoming more aware of cross contamination as technology and research identify true residual effect of cross contamination. President, Dan Hoyng stated: "The VERTA series is a wonderful compliment to the SafeShield(tm) germicidal skin protectant and Bontempi medical instrument line. This product launch maximizes revenue potential for the account managers with minimal cost increases to NBM. The VERTA series further strengthens NBM position in the still developing billion dollar industry of anti-microbial products." Hoyng further stated that NBM is committed to continue further research and development and acquisitions to expand its infection control product line.
|
